Article Text

PDF
Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomised controlled trial
  1. Ana Juanes1,
  2. Noe Garin1,2,
  3. Maria Antonia Mangues1,3,
  4. Sergio Herrera4,
  5. Mireia Puig4,
  6. Maria Jose Faus5,
  7. Maria Isabel Baena5
  1. 1 Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  2. 2 Instituto de Salud Carlos III, Centro de Investigacin Biomdica en Red de Salud Mental, CIBERSAM, Madrid, Spain
  3. 3 CIBER de Bioingeniera, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain
  4. 4 Emergency Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  5. 5 Pharmaceutical care Research Group, Universidad de Granada, Granada, Spain
  1. Correspondence to Ana Juanes, Pharmacy Department, Hospital de la Santa Creu i Sant Pau.Sant Antoni Maria Claret 167, 08025 Barcelona, Spain; ajuanes{at}santpau.cat

Abstract

Background The resolution of potential drug-related problems is a priority of pharmaceutical care programmes.

Objectives To assess the clinical impact on drug-related negative outcomes of a pharmaceutical care programme focusing on the resolution of potential drug-related problems, initiated in the emergency department for patients with heart failure (HF) and/or chronic obstructive pulmonary disease (COPD).

Methods Controlled trials, in which older adults (≥65 years) receiving four or more medications admitted to the emergency department for ≥12 hours for worsening of HF and/or COPD were randomised (1:1) to either a pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department (intervention group (IG)) or standard care (control group). Comparisons between the groups were made for the proportion of patients with drug-related negative outcomes, number of drug-related negative outcomes per patient, mean stay, patients readmitted within 180 days and 180-day mortality.

Results 118 patients were included, 59 in each group. Fewer patients in the IG had drug-related negative outcomes (37 (62.7%) vs 47 (79.7%) in the control group (p=0.042)). Fewer drug-related negative outcomes per patient occurred in the IG (56 (0.95 per patient) vs 85 (1.44 per patient) in the control group (p=0.01)). The mean stay was similar between groups (194.7 hours in the IG vs 242.5 hours in the control group (p=0.186)). No difference in revisits within 180 days was found (32 (54.24%) in the IG vs 22 (37.3%) in the control group (p=0.065)). 180-Day mortality was detected in 11 (18.6%) patients in the IG compared with 13 (22%) in the control group (p=0.647).

Conclusion A pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department has a favourable clinical impact, as it reduces the number and prevalence of drug-related negative outcomes. No difference was found in other outcome variables.

Trial registration number NCT02368548.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.